Dr. rer. nat. Marianne Kraus
ALK-Inhibitoren als potentielle Therapie bei Proteasom-Inhibitor-resistentem Multiplen Myelom
Oct 1, 2021
Fundamental Research - Oct 1, 2021 - Sep 30, 2023
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Lenka, Besse Andrej, Kraus Marianne
Immunoproteasome activity as a predictive marker and therapeutic target in hematological malignancies
Jul 1, 2021
Fundamental Research - Jul 1, 2021 - Dec 31, 2021
Automatically Closed
Project leader: Besse Andrej
Members: Kraus Marianne, Besse Lenka
The molecular landscape of proteasome inhibitor resistance of multiple myeloma in vivo
Jul 1, 2020We here aim to dissect the molecular landscape of MM that is acquiring resistance to the most active PI, carfilzomib (CFZ) in vivo. We therefore here extend our model to orthotopic growth conditions of MM in murine bone marrow under continuous select...
Fundamental Research - Jul 1, 2020 - Dec 31, 2023
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Andrej, Schwestermann Jonas, Kraus Marianne, Besse Lenka
Identifying and targeting the “Achilles’ heel” in proteasome inhibitor-resistant multiple myeloma
Oct 1, 2018The proposal aims at understanding the biology of proteasome inhibitor (PI)-refractory multiple myeloma (MM), in particular the specific vulnerabilities of PI-refractory MM, or so called “Achilles’ heel”, towards development of novel treatment option...
Fundamental Research - Oct 1, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Andrej, Kraus Marianne, Besse Lenka, Mendez Lopez Max
HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen
Nov 1, 2016Proteasominhibitor-Resistenz ist ein wichtiger unmet clinical need beim Multiplen Myelom (MM). Die Aktivität von next generation therapy (Daratumumab, Carfilzomib, Pomalidomid) ist hier bei ca. 30 % Partialremissionen (PR). Wir haben in vitro durch...
Fundamental Research - Nov 1, 2016 - Oct 31, 2018
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne, Bader Juergen, Besse Lenka, Besse Andrej
Improving the activity of proteasome inhibitors for potential treatment of
Mar 31, 2015Traditional chemotherapy fails to cure renal cell carcinoma (RCC), hence novel approaches and mechanisms need to be exploited.Proteotoxic stress-induced apoptosis can be induced in cancer cells by interfering with the homeostasis of protein biosynthe...
Fundamental Research - Mar 31, 2015 - Dec 7, 2018
Automatically Closed
Project leader: Abt Dominik
Members: Engeler Daniel, Driessen Christoph, Kraus Marianne, Bader Jürgen
Development and preclinical characterization of third-generation proteasome inhibitors
Jan 1, 2013After validation of the proteasome as a prime target for innovative oncology drugs, the peptide borate bortezomib was approved as first in class proteasome inhibiting drug. Bortezomib provides reversible inhibition of the proteasomal beta 1 and beta...
Clinical Studies - Jan 1, 2013 - Dec 31, 2015
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne
In vitro proteotoxic synergism of nelfinavir and carfilzomib in solid cancer cell lines
Jan 1, 2013HER2-positive breast cancer accounts for approximately 25-30% of all breast cancer cases, and carries a bad prognosis compared to HER2-negative breast cancer. Despite recent advances with the development of HER2-targeted treatments, mainly trastuzuma...
Fundamental Research - Jan 1, 2013 - Dec 31, 2014
Automatically Closed
Members: Driessen Christoph, Gibbons-Marsico Jennifer, Kraus Marianne
Praeklinische Charakterisierung neuer Einsatzmöglichkeiten von Proteasominhibitoren zur Vorbereitung innovativer klinischer Investigator-initiierter Studien in der Onkologie
Jul 1, 2012Zielsetzung: Das Projekt soll neue Möglichkeiten der Wirkung von Proteasominhibitoren auf maligne Zellen explorieren und die Grundlagen dazu legen, in späteren klinischen Studien innovative Einsatzmöglichkeiten von Proteasominhibitoren in rationalen,...
Fundamental Research - Jul 1, 2012 - Jun 30, 2013
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne, Tarantino Ignazio
Development of third-generation proteasome inhibitors for clinical applications
Jan 1, 2012Wir möchten untereinheit-spezifische Proteasominhibitoren entwickeln, die die Resistenzmechanismen gegen den bisherigen Standardproteasominhibitor Bortezomib überwinden sollen. In der Zellkultur wurde ein erstes Set von Peptid-Epoxyketonen und Vinyls...
Clinical Studies - Jan 1, 2012 - Dec 31, 2012
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne
In vitro Untersuchung der Proteasen-Aktivität und der Wirkung von Proteasen-Inhibitoren bei hämatolgischen Neoplasien
May 18, 2009Die Verfügbarkeit verschiedener Arten von Protease-Inhibitoren als therapeutisch zugelassene Substanzen ermöglicht es, diese Systeme als Angriffspunkte für die Entwicklung neuer antineoplastischer Therapien zu evaluieren. Das Ziel der in vitro Unters...
Clinical Studies - May 18, 2009 - May 18, 2020
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne, Frick Petra, Ruedlinger Luzia, Ahrens Christina, Algeni Annelies, Patzl Sigrid